← Back to all trials
Not Yet Recruiting
NCT05611372
Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
Conditions: REM Sleep Behavior Disorder, Parkinson Disease, Synucleinopathies
Sex: All
Ages: 30 Years – 75 Years
Phase: PHASE2, PHASE3
Enrollment: 732
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
To investigate whether a year of rasagiline may reduce the progression from idiopathic REM sleep behavior disorder (RBD) to Parkinson's disease (PD).
Eligibility Criteria
Inclusion Criteria:PSG confirmed RBD with subtle motor symptoms (4≤MDS-UPDRS-III≤10 at baseline)no clinical diagnosis of Parkinson's disease or dementia at baselineage 30-75no concomitant or previous use of any other anti-parkinson medicationsprovide written informed consentExclusion Criteria:diagnosed with secondary parkinsonism (eg., drug-induced, vascular, psychogenic)secondary RBD (eg., drug-induced, immune-mediated)nervous system comorbidities (eg., stroke, epilepsy, encephalitis)severe psychiatric comorbiditiesallergic to rasagilinesevere systemic diseases (eg., end-stage kidney disease, liver failure)
Source: ClinicalTrials.gov (NCT05611372). StuddyBuddy aggregates publicly available trial information.
